DDInter690 DDInter1409
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Tramadol
Tramadol {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Ethanol {u} (Compound) binds {v} (Gene) CYP4A11
CYP4A11 {u} (Gene) is bound by {v} (Compound) Rifampicin
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Tramadol (Compound) and Tramadol may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Ethanol (Compound) binds CYP4A11 (Gene) and CYP4A11 (Gene) is bound by Rifampicin (Compound) and Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a